- Sulbactam – Ceftriaxone combination provides the unique properties of a broad-spectrum antibiotic with an added advantage of a wide-spectrum Beta-lactamase inhibitor.
- Provides 94.6% Nigher clinical efficacy against Ceftriaxone resistant strain as compared to Ceftriaxone alone.
- Shows higher effectivity and bacterial eradication rate in respiratory and urinary tract infections as compared to cefoperazone/sulbactam.
- Provides higher clinical cured patients in lower RT as compared to Co-Amoxiclav.